News about 'drug discovery'

28 Aug 2012
On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS...
14 Aug 2012
We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ 2012 Annual Meeting at the Impiana KLCC Hotel in Kuala Lumpur, Malaysia on Wednesday, November 14. Also, we are sponsoring a lunch to allow the Sub-groups (Biology/Targets, Candidates, Critical Knowledge and Tools, and...
6 Jun 2012
Delamanid (OPC-67683) This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine ...
24 May 2012
For this week’s update, we highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Dooley KE, Mitnick C, Degroote MA, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N,...
30 Apr 2012
World TB Day Congressional Briefing Tuberculosis – We Can Beat this Global Killer Wednesday, March 21, 2012 A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Special areas...
10 Apr 2012
This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March. The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based. The second article by...
28 Mar 2012
Click here to access publication. The WGND Strategic Plan 2011-2015 is an update of the “New Drugs” section of the Global Plan to Stop TB: 2011-2015 . It describes the progress, gaps, and vision of the WGND and the TB drug development field as a whole. Since its inception, the WGND has served as a...
26 Mar 2012
The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved...
22 Feb 2012
Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Korduláková J, Chavadi SS, Morisseau C, Lenaerts AJ, Lee RE, McNeil MR, Jackson M. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol. 2012 Feb 19...
19 Jan 2012
Click here for brochure. Vincent V, Rigouts L, Nduwamahoro E, Holmes B, Cunningham J, Guillerm M, Nathanson CM, Moussy F, De Jong B, Portaels F, Ramsay A. The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. Int J Tuberc Lung Dis. 2012 Jan;16(1):...
13 Dec 2011
Dr. Yossef Av-Gay Summary: Dr. Yossef Av-Gay , a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in the Proceedings of the National Academy of Sciences (PNAS) entitled “ Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA...
7 Dec 2011
Click here for full report. Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released. This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been...
29 Nov 2011
Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D. Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against Tuberculosis . Cell Host Microbe. 2011 Nov 17;10(5):475-85. This week’s article...
7 Nov 2011
Gyanu Lamicchane Summary: Microbial geneticist Dr. Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in...
2 Nov 2011
Click here for full report Source: Stop TB Partnership News, November 3, 2011 A plan targeting researchers around the world and providing them with a framework to achieve the research objectives of the the Global Plan to Stop TB 2011-2015 and beyond, towards elimination of TB, was launched on...

Pages